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Dear Editor, 
 In their comparative retrospective cohort, Ahmad et al. [1] showed a higher rate of adverse events such 
as hospitalization, surgery, or delayed inflammatory bowel disease (IBD) treatment modification in 
patients with IBD tested positive with stool multiplex gastrointestinal pathogen panels (GPPs) for 
discrimination of diarrhea related to IBD exacerbation or infection, though positive predictive value of 
GPPs remained limited [1]. Gut microbiota of IBD patients includes a plethora of infectious species that 
could cause false positive results in GPP tests, thus delaying the decision of the appropriate treatment 
and reducing its clinical benefit [2]. Moreover, the interpretation of GPP test results in clinical practice is 
associated with some limitations, also mentioned by authors [1]. In this respect, several pathogens can 
occur not only asymptomatically (e.g., norovirus and Salmonella spp.) but also subclinically (e.g., 
Clostridium difficile non-toxigenic strains) in a colonization-like setting [3, 4], where connection with 
disease is uncertain. Additionally, an uncertainty exists regarding the cost-effectiveness of GPPs for 
suspected infectious gastroenteritis in hospital and community settings [5]. Interestingly, despite the 
well-described biases of GPPs in IBD [1] especially in terms of antimicrobial stewardship [6], all of the 
panels lack the capability to detect cytomegalovirus (CMV), which consists a substantial burden of IBD 
flares and steroids refractoriness being detected in 21–34% and 33–36% of these cases, respectively 
[7]. Nevertheless, even if GPPs were able to detect fecal CMV-DNA, the sensitivity of polymerase chain 
reaction (PCR) for CMV-genome in stools seems to remain inferior to its detection in tissue samples 
depending also on the viral load [8]. Another important aspect that should be introduced is the role of 
confocal endomicroscopy (CE), which rises in IBD flare identification, as specific characteristics to define 
IBD activity have been suggested in many studies. Although still experimental, the assessment of the 
crypt morphology (number of colonic crypts, crypt tortuosity, crypt lumen), erosions, vascularity, cellular 
infiltrates within the lamina propria, number of goblet cells, gut barrier disruption, and leakage of 
fluorescein to the lumen could detect immediately and non-invasively the etiology of symptom 
exacerbation among IBD patients [9–11]. Furthermore, Clostridium difficile is visible and recognizable 
in vivo in the gut mucosa under CE, irrespective of symptoms manifestation [12], whereas other over-
infections in patients with IBD have not been evaluated using CE, although it is known that these patients 
have intramucosal presence of bacteria more frequently than normal controls [9]. Nonetheless, this 
technique is still limited, lacking evidence-based data, expensive, and difficult to be performed to replace 
the conventional laboratory workup. Recently, by using the Luminex xTAG GPP, quantitative thresholds 
offer recognition of Clostridium difficile infection [13] which has been increasingly associated with IBD 
flares [14]. As deduced by the clinical necessity to differentiate IBD flares from over-infections beyond 
multiplex GPPs, further studies are required to develop and assess a novel, validated, and easy-to-
perform, grading diagnostic index including clinical, laboratory, microbiological, and endoscopic findings 
to increase the sensitivity of a secure and accurate diagnosis in IBD symptomatic patients and obtain 
the potentiality of an immediate intervention. 
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